8-K: Enovis Q3 Sales Up 9%, Raises 2025 Adjusted Guidance

Enovis Corporation reported strong third-quarter sales growth and raised its full-year 2025 adjusted EBITDA and EPS guidance, despite a significant non-cash goodwill impairment charge.

Summary

• Third-quarter net sales reached $549 million, marking a 9% increase on a reported basis and 7% organically compared to Q3 2024.
• Reconstructive sales grew 12% on a reported basis and 9% organically year-over-year.
• Prevention & Recovery (P&R) sales increased 6% on a reported basis and 4% organically.
• Reported a net loss of $571 million, or $9.99 per share, primarily due to a $548 million non-cash goodwill impairment charge.
• Adjusted EBITDA for the quarter was $95 million, or 17.3% of sales.
• Adjusted net earnings per diluted share were $0.75.
• Completed the divestiture of the Diabetic Footcare business unit (Dr. Comfort) from P&R in October 2025 for total proceeds of up to $60 million.
• Updated full-year 2025 revenue guidance to $2.24-2.27 billion, reflecting a $15 million reduction due to the Dr. Comfort divestiture.
• Raised full-year 2025 adjusted EBITDA guidance to $395-405 million (from $392-402 million).
• Raised full-year 2025 adjusted EPS guidance to $3.10-3.25 (from $3.05-3.20).

Sentiment

Score: 6

Explanation: Mixed sentiment. Strong organic sales growth and raised adjusted guidance are positive, indicating operational strength. However, the very large non-cash goodwill impairment charge leading to a significant net loss is a major negative, raising questions about asset valuations, even if it doesn't impact future cash operations directly. The company's focus on adjusted metrics attempts to mitigate the impact of the impairment.

Positives

• Strong diversified growth platform delivered 9% reported sales growth and 7% organic growth in Q3 2025.
• Reconstructive sales showed robust performance with 12% reported growth and 9% organic growth.
• Prevention & Recovery sales also contributed positively with 6% reported growth and 4% organic growth.
• Full-year 2025 adjusted EBITDA guidance was raised to $395-405 million.
• Full-year 2025 adjusted earnings per share guidance was raised to $3.10-3.25.
• Adjusted net income from continuing operations increased to $43.5 million in Q3 2025 from $41.0 million in Q3 2024.

Negatives

• Reported a significant net loss of $571 million in Q3 2025, compared to a net loss of $31.3 million in Q3 2024.
• A substantial non-cash goodwill impairment charge of $548 million was recorded, impacting reported net loss.
• Net loss per share was $9.99, a significant increase from $0.58 in the prior year quarter.
• Full-year 2025 revenue guidance was slightly lowered to $2.24-2.27 billion, primarily due to the Dr. Comfort divestiture.

Risks

• Risks related to the acquisition of Lima.
• Potential impact of public health emergencies and global pandemics.
• Disruptions in the global economy due to escalating geopolitical tensions, including Russia's invasion of Ukraine.
• Macroeconomic conditions, such as inflationary pressures.
• Changes in government trade policies, including the implementation of tariffs.
• Impact of U.S. government shutdowns.
• Supply chain disruptions.
• Increasing energy costs and availability concerns, particularly in the European market.
• Other factors detailed in the company's Annual Report on Form 10-K under 'Risk Factors'.

Future Outlook

Enovis updated its financial expectations for full-year 2025, forecasting revenue in the range of $2.24-2.27 billion, adjusted EBITDA of $395-405 million, and adjusted earnings per share of $3.10-3.25. The revenue guidance includes a $15 million reduction due to the Dr. Comfort divestiture, while adjusted EBITDA and EPS guidance were raised.

Management Comments

• "We delivered solid results in the third quarter, reflecting continued progress by our teams around the world. Execution was driven by double-digit growth in extremities and consistent performance across Prevention & Recovery."
• "As we position Enovis for its next phase of profitable, capital-efficient growth, we are focusing on the near-term strategic priorities of commercial execution and innovation, operational excellence, and financial discipline."

Industry Context

Enovis operates in the medical technology sector, focusing on clinically differentiated solutions for patient outcomes and motion restoration. The reported growth in Reconstructive and P&R segments suggests continued demand in these areas, aligning with broader trends in an aging population and increasing focus on active lifestyles. The divestiture of the Diabetic Footcare business indicates a strategic portfolio optimization, potentially to focus on higher-growth or higher-margin core medical technology segments.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: Impacted by the significant non-cash goodwill impairment charge affecting book value, but also by positive adjusted financial guidance and sales growth.
• Employees: Integration activities related to acquisitions may involve payroll and retention costs for roles to be eliminated.
• Customers: Benefit from continued innovation and clinically differentiated solutions aimed at enhancing patient outcomes and restoring motion.

Next Steps

• Host an investor conference call and live webcast on November 6, 2025, at 8:30 am ET to discuss financial results.

Key Dates

Recommendation

While Enovis demonstrated solid organic sales growth and raised its full-year adjusted guidance, the substantial non-cash goodwill impairment charge of $548 million is a significant concern. This impairment, even if non-cash, reflects a re-evaluation of asset values and could signal underlying issues or overvaluation in prior acquisitions. The market will likely weigh the operational positives (growth, raised adjusted guidance) against the balance sheet negative (impairment). A 'hold' recommendation is prudent until further clarity emerges on the implications of the impairment and the sustainability of adjusted growth.

Keywords

Medical Technology, Orthopedics, Reconstructive Surgery, Prevention & Recovery, Financial Results, Earnings, Guidance, Goodwill Impairment, Divestiture, Enovis